5/1/09 update
Although I came down with a touch of the flu (hopefully, not swine) while in NYC, it seems Wall Street remains inoculated to viruses and most everything else. And for the two weeks since my last update the Nasdaq Composite Index continued its climb, closing Friday up 9.39% CYTD, or Contest Year To Date, (vs. up 6.46% CYTD at its 4/17/09 close). Somewhat ironically, contrary to the vitality of the broader market, biotechs had less than a healthy two weeks. At Friday's close, the NBI was down -6.71% CYTD (vs. down -6.07% CYTD at its 4/17/09 close), while the Contest median was down -5.74% CYTD (vs. down -2.52% CYTD at its 4/17/09 close).
Despite being whacked by the SQNM blow-up, RKRW's portfolio still managed to inch by GEORGIA's DNDN-fueled portfolio to take first place, with PRAVN's portfolio holding on to the third position. The end of the week CYTD percentages are: RKRW up 38.07%, GEORGIA up 37.54% and PRAVN up 30.53%.
At Friday's close, 14 of the 32 Contest portfolios were in the black and 17 of the 32 were beating the NBI.
I've reallocated the proceeds of Deerfields's $.8585 buyout of NTMD, using the 4/28 closing prices (which is the date the proceeds were deposited in my real world brokerage account).
Have a flu-free weekend folks!
Below is the Top Ten list on 5/1/09:
5/1/09
Rank Name Profit/Loss
1 RKRW 38,072
2 GEORGIA 37,541
3 PRAVN 30,529
4 GENE 27,156
5 BULBA 23,753
6 ASHLEY 12,621
7 SCARAM 10,164
8 MIKE 8,648
9 NIGEL 7,351
10 ENZYME 7,328
(All corrections, especially adjustments for splits, greatly appreciated.) |
